Sep 29, 2021 6:48am EDT NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
Sep 27, 2021 7:04am EDT NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil)
Sep 08, 2021 7:48am EDT NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Aug 30, 2021 8:06am EDT NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
Aug 26, 2021 6:48am EDT NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies
Aug 23, 2021 9:33am EDT Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary
Aug 18, 2021 11:53am EDT NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19
